Statin
Mostrando 1-12 de 103 artigos, teses e dissertações.
-
1. Como manejar a interação entre anlodipino e sinvastatina?
Em pacientes que fazem uso de anlodipino e sinvastatina, a dose de sinvastatina não deve ultrapassar 20 mg por dia. Essa restrição deve-se ao risco de elevação do nível sérico de sinvastatina e ao aumento do risco de miopatia, incluindo rabdomiólise. O mecanismo dessa interação é incerto, mas pode envolver competição pelo CYP3A, pois os dois
Núcleo de Telessaúde Rio Grande do Sul. Publicado em: 12/06/2023
-
2. Há risco de incidência de Diabetes Mellitus tipo 2 (DM2) em doentes medicados com estatinas?
O uso de estatinas está associado a um aumento na ocorrência de diabetes
(OR 1,09; IC 95% (1,02a 1,17)
, especialmente em obesos, mulheres, idosos, descendentes de asiáticos, síndrome metabólica
, glicemia alta em jejum e com hemoglobina glicada alta (HbA1c > 6%). Em metanálise observou-se maior risco entre os doentes tratados com
Núcleo de Telessaúde Santa Catarina. Publicado em: 12/06/2023
-
3. Effects of statin response on cardiovascular outcomes in patients with ST-segment elevation myocardial infarction
SUMMARY OBJECTIVE: This study aimed to evaluate the effects of statin response on cardiovascular outcomes in patients with ST-segment elevation myocardial infarction. METHODS: A total of 1029 ST-segment elevation myocardial infarction patients were enrolled in the study. The patients who failed to achieve >40% reduction in baseline low-density lipoprotein
Revista da Associação Médica Brasileira. Publicado em: 2022
-
4. Predictors of left ventricular ejection function decline in young patients with ST-segment elevation myocardial infarction
SUMMARY OBJECTIVE: A decrease in the left ventricular ejection fraction (≤40%) in the setting of ST-segment elevation myocardial infarction is a significant predictor of mortality in the young ST-segment elevation myocardial infarction population. In this study, we aimed to investigate the predictors of left ventricular ejection fraction reduction and eva
Revista da Associação Médica Brasileira. Publicado em: 2022
-
5. Choosing statins: a review to guide clinical practice
ABSTRACT Statins are among the most widely prescribed medicines in the world and have proved their value in reducing cardiovascular events and mortality. Many patients report adverse effects that lead to interruption of treatment. This review aims to individualize statin treatment, considering efficacy for reducing cardiovascular risk and safety, in the sett
Arch. Endocrinol. Metab.. Publicado em: 2020-12
-
6. Lipid profile and response to statin therapy in patients with hypopituitarism
ABSTRACT Objective: Dyslipidemia is prevalent among patients with hypopituitarism, especially in those with growth hormone (GH) deficiency. This study aimed to evaluate the response to statin therapy among adult patients with dyslipidemia and hypopituitarism. Subjects and methods: A total of 113 patients with hypopituitarism following up at a neuroendocrin
Arch. Endocrinol. Metab.. Publicado em: 2020-12
-
7. Synergic effect of simvastatin in combination with amphotericin B against environmental strains of Cryptococcus neoformans from northeastern Brazil: a prospective experimental study
BACKGROUND: Statins are used as cholesterol-lowering drugs and may also have direct antimicrobial effects. OBJECTIVE: To evaluate synergic interactions between simvastatin and both amphotericin B and fluconazole, against environmental strains of Cryptococcus neoformans isolated from captive birds’ droppings. DESIGNAND SETTING: Experimental study cond
Sao Paulo Med. J.. Publicado em: 2020-02
-
8. Lipid profile and statin use in critical care setting: implications for kidney outcome
RESUMO Objetivo: Determinar se o uso pré-admissão hospitalar de estatina está associado com menor necessidade de diálise e/ou óbito durante internação em unidade de terapia intensiva. Métodos: Análise de coorte prospectiva. Foram incluídos consecutivamente 670 pacientes admitidos na unidade de terapia intensiva de um hospital acadêmico de cuidad
Einstein (São Paulo). Publicado em: 30/05/2019
-
9. PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
Resumo A doença arterial coronariana (DAC) é uma das principais causas de mortalidade. Níveis circulantes elevados de lipoproteína de baixa densidade (LDL) no sangue estão associados com mortalidade cardiovascular, seja por um papel etiológico ou por sua associação com a progressão da DAC em si. Estudos clínicos randomizados mostram que, quando os
Arq. Bras. Cardiol.. Publicado em: 28/02/2019
-
10. Factors associated with statin-related adverse muscular events in adult dyslipidemic outpatients
ABSTRACT Statins are the most prescribed lowering-cholesterol drugs. They are well tolerated, however, some patients present muscular adverse symptoms. Clinical and laboratory data from 120 dyslipidemic patients prescribed with statins were obtained from January to December/2013 at a University Hospital in Sao Paulo city, Brazil, to study factors associated
Braz. J. Pharm. Sci.. Publicado em: 09/04/2018
-
11. Evaluation of the Effects of Atorvastatin and Ischemic Postconditioning Preventing on the Ischemia and Reperfusion Injury: Experimental Study in Rats
Abstract Introduction: Reperfusion injury leads to systemic morphological and functional pathological alterations. Some techniques are already estabilished to attenuate the damage induced by reperfusion. Ischemic preconditioning is one of the standard procedures. In the last 20 years, several experimental trials demonstrated that the ischemic postconditioni
Braz. J. Cardiovasc. Surg.. Publicado em: 2018-02
-
12. Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study
This study aimed to test the effects of xuezhikang, a cholestin extract that contains statin-like components, on arterial stiffness in patients with essential hypertension. One hundred hypertensive patients from the Chinese PLA General Hospital were randomly allocated to receive xuezhikang (1200 mg/day, orally) or placebo (same capsules containing only pharm
Braz J Med Biol Res. Publicado em: 31/08/2017